LEI Zhenyun, XUE Guozhong, LIU Zhenhua, ZHANG Xinli. Research progress on action mechanism of NLRP3 inflammasome and pyroptosis in diabetic nephropathy[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0543
Citation: LEI Zhenyun, XUE Guozhong, LIU Zhenhua, ZHANG Xinli. Research progress on action mechanism of NLRP3 inflammasome and pyroptosis in diabetic nephropathy[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0543

Research progress on action mechanism of NLRP3 inflammasome and pyroptosis in diabetic nephropathy

Funds: 

Regional Project of National Natural Science Foundation of China (82160865)

More Information
  • Received Date: July 14, 2024
  • Accepted Date: October 20, 2024
  • Available Online: April 01, 2025
  • Diabetic nephropathy (DN), as one of the most common complications of diabetes, is a primary cause of end-stage renal disease. The pathogenesis of DN encompasses processes such as chronic inflammation, recruitment and activation of immune cells, tubular and glomerular injury, and renal fibrosis. These processes are highly correlated with the activation of the nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome and the resulting pyroptosis it mediates. Previous studies have shown that the release of pro-inflammatory cytokines, leakage of damage-associated molecular patterns (DAMPs), recruitment and activation of immune cells can be reduced by regulating the NLRP3 inflammasome and its mediated pyroptosis, thereby slowing the diffusion of inflammatory responses in adjacent cells, fibrosis, and tissue remodeling processes. Ultimately, these process can improve renal injury and dysfunction caused by diabetic nephropathy. This article further elucidates the molecular regulatory mechanisms of the NLRP3 inflammasome and its mediated pyroptosis at different pathological stages of DN, proposes potential targets for regulating their activation, and provides a new direction for personalized treatment of DN.
  • Related Articles

    [1]LIU Shupeng, YU Mengyang, WU Xiaofei, WANG Hongyun. Clinical Landscape of Therapeutic Cancer Vaccines: Challenges and Opportunities[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1356-1363. DOI: 10.12290/xhyxzz.2024-0130
    [2]WEN Xuejun, ZHOU Wuhao, GUO Zhide, ZHANG Xianzhong. Integrin αvβ3 Targeted Radiopharmaceutical 99mTc-RGD Combined with Anti-PD-L1 mAb to Enhance the Anti-tumor Effect in Tumor Immunotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 766-773. DOI: 10.12290/xhyxzz.2023-0155
    [3]LI Tao, ZHANG Kan, YANG Wenyu, LIU Lu, ZHENG Xuan, ZHANG Fan, HU Yi. Clinical Application of Immune Checkpoint Inhibitors CTLA-4 in Solid Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 652-659. DOI: 10.12290/xhyxzz.2022-0617
    [4]WANG Shuo, DENG Yuntian, PENG Huan, ZHANG Xiangfeng. Progress in the Treatment of Non-small Cell Lung Cancer with Immune Checkpoint Inhibitors[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 409-415. DOI: 10.12290/xhyxzz.2022-0151
    [5]LI Linrong, LI Yan, SUN Qiang. Clinical Trials and Current Progress in the Treatment of Triple-negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 177-183. DOI: 10.12290/xhyxzz.2022-0085
    [6]LUO Xiangchong, WANG Zhouqing, LI Qiongyan, MAO Guibing, AN Le, ZHU Jiahong, TAO E'hong, SUN Lifei, WANG Shengfei, LI Gaofeng. Pharmacological Effects and Clinical Evaluation of PD-1 Inhibitor of Tislelizumab in the Treatment of Advanced Malignant Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 679-686. DOI: 10.12290/xhyxzz.2021-0691
    [7]LUO Yanwen, ZHU Qingli. Application of Radiomics in Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 983-988. DOI: 10.12290/xhyxzz.2021-0011
    [8]HUA Yuwei, ZHAO Lin. Diagnosis and Management of Immunotherapy-related Liver Toxicity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 798-806. DOI: 10.12290/xhyxzz.2021-0138
    [9]Mei GUAN, Chun-mei BAI. Medical Treatment for Biliary Tract Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 325-333. DOI: 10.3969/j.issn.1674-9081.20190247
    [10]Han-zhong LI, Yu-shi ZHANG, Guo-yang ZHENG. Commentary on and Expectation of Tumor Immunotherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 289-294. DOI: 10.3969/j.issn.1674-9081.2018.04.001
  • Cited by

    Periodical cited type(5)

    1. 姚晓倩,洪敏萍,蔡宏杰,吴慧青. 基于超声影像组学术前预测浸润性乳腺癌患者腋窝淋巴结状态. 现代实用医学. 2023(01): 116-119 .
    2. 林文华,杨少玲,赫兰,陶均佳,张红珍,顾家红,赵坤,胡静. 基于术前超声及钼靶特征的列线图预测乳腺癌腋窝淋巴结转移的价值. 中国临床医学影像杂志. 2023(09): 647-653 .
    3. 牛梓涵,朱庆莉,姜玉新. 超声在早期乳腺癌腋窝淋巴结转移诊断中的应用进展. 中华超声影像学杂志. 2023(10): 889-893 .
    4. 李玥,曹军英. 多模态超声在乳腺癌精准诊断中研究进展. 临床军医杂志. 2022(07): 661-665 .
    5. 赵萍,闫朝岐,杨学伟,李洋,叶倩. 乳腺癌腋窝淋巴结超声检查评价及研究进展. 中国临床研究. 2022(09): 1270-1272+1291 .

    Other cited types(5)

Catalog

    Article Metrics

    Article views PDF downloads Cited by(10)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close